by admin | Jul 24, 2023 | press-releases
Home PRESS RELEASE CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with cretostimogene grenadenorepvec in BCG-Unresponsive High-Risk NMIBC 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱...
by admin | May 3, 2023 | press-releases
Home PRESS RELEASE CG Oncology Announces New Phase 2 Data with cretostimogene grenadenorepvec in Combination with pembrolizumab in BCG-Unresponsive NMIBC 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER...
by admin | Apr 10, 2023 | press-releases
Home PRESS RELEASE New Phase 2 Data with cretostimogene grenadenorepvec in Combination with pembrolizumab in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO...
by admin | Dec 27, 2022 | press-releases
Home PRESS RELEASE CG Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER =============================== --> Listen to this article...
by admin | Nov 15, 2022 | press-releases
Home PRESS RELEASE CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER...
by admin | Nov 10, 2022 | press-releases
Home PRESS RELEASE CG Oncology Presents New Phase 2 Data with cretostimogene grenadenorepvec in Combination with pembrolizumab in Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin 💻 DESKTOP AUDIO PLAYER =============================== -->...